---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-24-012144"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:33:28.094036+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ANI closes $316.25M convertible notes offering; upsizes due to demand

## Summary
- $316.25M aggregate principal of 2.25% convertible senior notes due 2029 issued; upsized from $250M initial offering.
- Net proceeds of ~$306.8M; $40.6M used for capped call transactions to reduce potential dilution.
- Remainder plus cash on hand used to repay ~$292.5M outstanding under existing senior secured credit agreement.
- Entered new $400M credit facility ($325M delayed draw term loan + $75M revolver) to partially finance pending Alimera Sciences merger.
- Capped call transactions cap price $114.02/share, a 100% premium over $57.01 closing price on pricing date.

## SEC filing metadata
- accession: 0000950103-24-012144
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 1.02, 2.03, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000095010324012144/0000950103-24-012144-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000095010324012144/dp216536_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-24-012144
- JSON: https://secwatch.observer/filing/0000950103-24-012144.json
- Plain text: https://secwatch.observer/filing/0000950103-24-012144.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.